Aspegic 325

Role

Indications

Reactions

Secondary

Drug Use For Unknown Indication	33.6%
Product Used For Unknown Indication	8.7%
Drug Exposure During Pregnancy	6.7%
Partial Seizures	6.7%
Myocardial Infarction	6.0%
Coronary Arterial Stent Insertion	5.7%
Infarction	4.4%
Acute Myocardial Infarction	3.4%
Acute Coronary Syndrome	3.0%
Lung Disorder	3.0%
Hiv Infection	2.7%
Arterial Injury	2.0%
Influenza Like Illness	2.0%
Pain	2.0%
Prophylaxis	2.0%
Deep Vein Thrombosis	1.7%
Foetal Exposure During Pregnancy	1.7%
Phlebitis	1.7%
Stent Placement	1.7%
Atrial Fibrillation	1.3%

Agranulocytosis	12.9%
International Normalised Ratio Increased	11.3%
Thrombocytopenia	8.1%
Jaundice	6.5%
Rectal Haemorrhage	6.5%
Cholangitis	4.8%
Pain In Extremity	4.8%
Tongue Haemorrhage	4.8%
Ulcerative Keratitis	4.8%
Abortion Induced	3.2%
Dysmorphism	3.2%
Gastric Haemorrhage	3.2%
Haematoma	3.2%
Maternal Drugs Affecting Foetus	3.2%
Oesophageal Haemorrhage	3.2%
Pancytopenia	3.2%
Prothrombin Level Decreased	3.2%
Pruritus	3.2%
Renal Failure	3.2%
Renal Failure Acute	3.2%

Concomitant

Product Used For Unknown Indication	17.8%
Drug Use For Unknown Indication	15.3%
Multiple Myeloma	8.9%
Hiv Infection	8.3%
Sedation	5.3%
Ill-defined Disorder	4.9%
Hypertension	4.1%
Benign Prostatic Hyperplasia	3.6%
Prophylaxis	3.4%
Hypovolaemia	3.1%
Septic Shock	3.1%
Myocardial Infarction	2.9%
Haemodynamic Instability	2.8%
Infection	2.6%
Prophylaxis Against Gastrointestinal Ulcer	2.6%
Acute Coronary Syndrome	2.4%
Analgesic Therapy	2.4%
Liver Transplant	2.3%
Pain	2.1%
Psychotic Disorder	2.1%

Varicella	14.9%
Vomiting	8.3%
Acute Coronary Syndrome	7.4%
General Physical Health Deterioration	7.4%
Pyrexia	6.6%
Renal Failure Acute	5.8%
Drug Rash With Eosinophilia And Systemic Symptoms	5.0%
Thrombocytopenia	5.0%
Cerebrovascular Accident	3.3%
Cytolytic Hepatitis	3.3%
Drug Interaction	3.3%
Dyspnoea	3.3%
Haematemesis	3.3%
Leukocytoclastic Vasculitis	3.3%
Myalgia	3.3%
Pancreatitis Acute	3.3%
Phlebitis	3.3%
Rectal Haemorrhage	3.3%
Rhabdomyolysis	3.3%
Septic Shock	3.3%